GelTex Pharmaceuticals (GELX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GelTex Pharmaceuticals (GELX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: lwd who wrote (123)	1/13/2000 2:51:00 PM
From: JMarcus	of 127

I spoke briefly to CFO Paul Mellett today. He's mailing me a printout of the slide show used for the H&Q presentation. The WLA Phase II cancer study of DENSPM will continue through the end of this year. The good news is that GELX intends vigorously to pursue filing INDs in 3 or 4 of SUNP's pipeline drugs. SUNP had hoped to file the INDs itself during 1999, but it needed to find a financial partner. GELX has the resources to file the INDs and proceed with Phase I trials on its own. It does not need, nor does it intend to seek, a partner for these drug candidates at this early stage. This is the big advantage that SUNP's executives saw in the merger, because the size of your royalty will be much smaller if you out-license a product at a very early stage in the development cycle. GELX stands to realize for its shareholders much more value from the SUNP pipeline than SUNP could ever have done on its own. DEHOP (for refractory diarrhea) is still on hold, while GELX evaluates its side effect profile. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next